<DOC>
	<DOCNO>NCT00811226</DOCNO>
	<brief_summary>The purpose study determine efficiency Olmesartan medoxomile ( OLMETEC® ) alone combination hydrochlorothiazide ( OLMETEC PLUS® ) reduction arterial blood pressure patient light moderate hypertension , evaluate percentage patient reach treatment goal use antihypertensive regimen .</brief_summary>
	<brief_title>Assessment Effectiveness OLMETEC® OLMETEC PLUS® Treatment Hypertension Stage I II Patients ( Study P05254 ) ( COMPLETED )</brief_title>
	<detailed_description>α= 0.05. α 's Z=1.96 β= 80 % . β 's Z=0.84 Estimated proportion subject achieve optimal control arterial hypertension= 83.2 % 450 subject expect enrol study 40 subject enrol Venezuela .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Men woman 18 year age older Essential arterial hypertension Stade I II accord JNC VII Signature Informed Consent Secondary arterial hypertension Pregnant woman lactancy Recent cardiovascular disease , heart attack , unstable angina , procedure coronary revascularization previous six month . Acute Coronary Failure Syndrome previous six month . Chronic Ischemic Cardiopathy Treatment . Cerebral Vascular Disease previous six month . Alcoholism Story use drug two previous year . Hepatic Disease Story Chronic Renal Failure define serumal creatinine high 2mg/dl Albuminuria high 1gr . Known Allergy blocker angiotensine II receptor . Neoplasmic Malignant Disease include leukemia lymphoma ( Skin basocellular cancer include ) Auto Immune Disorders systemic erythematosus lupus . Non attachment medical treatment history . Patients share clinical investigation essay last 3 month . Congestive heart failure previous treatment ECA inhibitor . Allergy thiazidic diuretic . Angioedema History Use drug affect potassium secretion , diuretic saver potassium , angiotensine enzyme inhibitor , betablockers , nonsteroid antiinflammatory drug . Potassium consumption orally</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Hypertension Stage I</keyword>
	<keyword>Hypertension Stage II</keyword>
</DOC>